Streetbeat News

Earnings

GS

Recent options trading activity for Goldman Sachs Gr (NYSE:GS) shows a bearish sentiment among investors, with 55% of trades being bearish and 44% bullish. The trading volume and open interest suggest a price target range of $370.0 to $420.0. Notable options activity includes both puts and calls with varying sentiments and expiration dates. Goldman Sachs, a leading investment bank, has seen its stock price increase by 0.51% to $395.17, with an upcoming earnings report in 47 days.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:17 pm

SOUN

SoundHound AI Inc (NASDAQ:SOUN) is in focus ahead of its Q4 earnings report, expected to post a loss of 6 cents per share with $17.746 million in revenue. The stock surged over 70% in the last five sessions and nearly 300% in the last month, partly due to speculation about AI in cellular tech and Nvidia's investments. Northland Capital Markets downgraded the stock from Outperform to Market Perform. Shares were up 9.46% at $6.94 at the time of writing.

Portfolio Pulse from Adam Eckert

February 29, 2024 | 3:16 pm

SQM

Sociedad Quimica Y Minera (SQM) shares are trading higher after the company reported its Q4 earnings.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:15 pm

CC

OKTA

SNOW

PCE data matched forecasts, influencing market sentiment. Okta's stock surged due to optimistic future guidance, while Snowflake's shares fell. Chemours experienced a decline after announcing executive changes and a delay in filing its 10-K report.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:10 pm

BGNE

BeiGene announced an efficacy analysis comparing its drug BRUKINSA to acalabrutinib in treating relapsed or refractory chronic lymphocytic leukemia. The analysis suggests an efficacy advantage of BRUKINSA over acalabrutinib, addressing questions and limitations of previous analyses.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:07 pm

CC

Chemours shares dropped following the announcement of executive changes and the delay of its fourth quarter results and 10-K filing.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:04 pm

MQ

In the past three months, Marqeta (NASDAQ:MQ) received varied analyst ratings, with a recent shift towards more bullish perspectives. The average 12-month price target for MQ is now $8.00, up from $7.25, indicating a positive outlook. Analysts from firms like Truist Securities and Barclays have adjusted their ratings and price targets, reflecting optimism about Marqeta's future performance despite its current financial challenges, including a significant revenue decline and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:01 pm

ACU

Acme United (AMEX:ACU) is scheduled to release its quarterly earnings report on 2024-03-01, with analysts expecting an EPS of $0.55. The company's past earnings performance shows a mix of beats and misses, with the stock price generally reacting positively the following day. Shares are currently trading at $46.45, up 84.93% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm

RPID

Rapid Micro Biosystems (NASDAQ:RPID) is scheduled to release its quarterly earnings report on March 1, 2024, with an expected EPS of $-0.30. Historical data shows mixed reactions to past earnings, with the stock price fluctuating based on actual EPS outcomes and guidance. Over the last year, RPID shares have declined by 19.35%, indicating potential concern among long-term investors as they await this earnings announcement.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm

BBAI

BFRG

SOUN

Shares of AI stocks are experiencing an uptrend, potentially due to C3.ai's strong Q3 financial results. This positive performance could be influencing investor sentiment towards AI-focused companies.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:00 pm